Last reviewed · How we verify
BIO101
BIO101 is a small molecule targeting the SARM1 protein to prevent mitochondrial dysfunction.
BIO101 is a small molecule targeting the SARM1 protein to prevent mitochondrial dysfunction. Used for Amyotrophic lateral sclerosis (ALS).
At a glance
| Generic name | BIO101 |
|---|---|
| Also known as | Sarconeos (BIO101), 20 hydroxyecdysone (20E) |
| Sponsor | Biophytis |
| Drug class | SARM1 inhibitor |
| Target | SARM1 |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
BIO101 works by inhibiting the SARM1 protein, which is involved in the activation of the NAD+ breakdown pathway. This leads to a decrease in the production of toxic aldehydes that cause mitochondrial dysfunction. By preventing mitochondrial dysfunction, BIO101 aims to slow down or halt the progression of various diseases.
Approved indications
- Amyotrophic lateral sclerosis (ALS)
Common side effects
- Gastrointestinal disorders
- Musculoskeletal disorders
Key clinical trials
- Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss. (PHASE2)
- A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT) (PHASE2)
- Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIO101 CI brief — competitive landscape report
- BIO101 updates RSS · CI watch RSS
- Biophytis portfolio CI